These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 26176848)

  • 21. Efficacy and safety of enteric-coated mycophenolate sodium in patients with de novo and maintenance renal transplantation.
    Qin Y; Zhang F; Shen B; Liu Y; Qiu J; Guo Y; Fan Y
    Int J Clin Pract Suppl; 2014 Apr; (181):17-22. PubMed ID: 24673715
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior efficacy of enteric-coated mycophenolate vs mycophenolate mofetil in de novo transplant recipients: pooled analysis.
    Salvadori M; Bertoni E; Budde K; Holzer H; Civati G; Lien B; Arns W
    Transplant Proc; 2010 May; 42(4):1325-8. PubMed ID: 20534293
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation.
    Belliere J; Esposito L; Gandia P; Duffas JP; Sallusto F; Cardeau-Desangles I; Del Bello A; Rostaing L; Kamar N
    Ann Transplant; 2014 Feb; 19():76-81. PubMed ID: 24509827
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
    Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
    Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteric-coated mycophenolate sodium: therapeutic equivalence to mycophenolate mofetil in de novo renal transplant patients.
    Sollinger H
    Transplant Proc; 2004 Mar; 36(2 Suppl):517S-520S. PubMed ID: 15041399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients.
    Kamar N; Rostaing L; Cassuto E; Villemain F; Moal MC; Ladrière M; Barrou B; Ducloux D; Chaouche K; Quéré S; Di Giambattista F; Be F
    Clin Nephrol; 2012 Feb; 77(2):126-36. PubMed ID: 22257543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium?
    Ding C; Xue W; Tian P; Ding X; Pan X; Xiang H; Tian X; Li Y; Zheng J
    Int J Clin Pract Suppl; 2014 Apr; (181):10-6. PubMed ID: 24673714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine.
    Nashan B; Suwelack B; Ivens K; Arns W; Lhotta K; Bourbigot B; Budde K; Fischer W; Pietruck F;
    Transplant Proc; 2006 Nov; 38(9):2856-9. PubMed ID: 17112848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients.
    Salvadori M;
    Transplant Proc; 2005 Mar; 37(2):909-11. PubMed ID: 15848572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients.
    Huang HF; Yao X; Chen Y; Xie WQ; Shen-Tu JZ; Chen JH
    Int J Clin Pract Suppl; 2014 Apr; (181):4-9. PubMed ID: 24673713
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium: results of a 1-year extension study.
    Budde K; Knoll G; Curtis J; Kahana L; Pohanka E; Seifu Y; Neumayer HH
    Transplant Proc; 2005 Mar; 37(2):912-5. PubMed ID: 15848573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
    Cai L; Zeng F; Liu B; Wei L; Chen Z; Jiang J
    Int J Clin Pract Suppl; 2014 Apr; (181):23-30. PubMed ID: 24673716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: results of a 12-month multicenter, open-label, prospective study.
    Vogt B; Antoniadis A; Klinger M; Vitko S
    Transplant Proc; 2006 Jun; 38(5):1301-6. PubMed ID: 16797288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China.
    Wang Z; He JJ; Liu XY; Lin B; Zhang L; Geng L; Zheng S
    Immunopharmacol Immunotoxicol; 2015; 37(6):508-12. PubMed ID: 26525836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A
    Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study.
    Yin H; Qiu K; Hu XP; Li XB; Wang W; Liu LH; Zhang XD
    Int J Clin Pract Suppl; 2014 Apr; (181):31-7. PubMed ID: 24673717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M; Girón F; Hernández E; Juarez F; Liendo C; Novoa P; Toledo M;
    Transplant Proc; 2004; 36(6):1647-9. PubMed ID: 15350440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients.
    Graff J; Scheuermann EH; Brandhorst G; Oellerich M; Gossmann J
    Ther Drug Monit; 2016 Jun; 38(3):388-92. PubMed ID: 26829599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F; Rosich E; Arias M; Torregrosa V; Oppenheimer F; Campistol JM
    Transplant Proc; 2007 Sep; 39(7):2179-81. PubMed ID: 17889130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bunnapradist S; Sampaio MS; Wilkinson AH; Pham PT; Huang E; Kuo HT; Anastasi B; Danovitch GM; Lo SK
    Am J Nephrol; 2014; 40(2):184-90. PubMed ID: 25196230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.